Daily Sepsis Research Analysis
Analyzed 26 papers and selected 3 impactful papers.
Summary
Analyzed 26 papers and selected 3 impactful articles.
Selected Articles
1. Aptamer targeting HMGB1 attenuates inflammatory disease via domain-specific antagonism.
ZH-1a is a high-affinity DNA aptamer that binds the proinflammatory B-box of HMGB1, neutralizing extracellular HMGB1 signaling. In murine models, it reduces late-phase inflammation, improves survival in polymicrobial sepsis, and mitigates organ injury, supporting HMGB1-neutralization as a sepsis immunotherapy strategy.
Impact: Provides domain-specific HMGB1 neutralization with in vivo survival benefit in sepsis, opening an aptamer-based therapeutic avenue for late-phase inflammatory injury.
Clinical Implications: Supports pursuing HMGB1-targeted therapies for late-phase sepsis; aptamers may offer specificity and manufacturability advantages. Translation will require toxicology, PK/PD, and early-phase sepsis trials with biomarker-guided enrollment.
Key Findings
- ZH-1a binds the HMGB1 B-box with high affinity (Kd = 2.1 nM) and neutralizes extracellular HMGB1.
- Attenuated cytokine secretion and NF-κB activation in macrophages in response to HMGB1.
- Reduced late-phase systemic inflammation and organ injury in endotoxemia and improved survival in polymicrobial sepsis.
- Enhanced efficacy of methotrexate and mitigated disease in collagen-induced arthritis, indicating broader anti-inflammatory potential.
Methodological Strengths
- Mechanistic targeting with domain-specific aptamer validated across multiple in vitro and in vivo models.
- Demonstrated survival benefit in a polymicrobial sepsis model, addressing clinically relevant endpoints.
Limitations
- Preclinical models may not fully recapitulate human sepsis heterogeneity and timing.
- Safety, immunogenicity, and pharmacokinetics of ZH-1a in humans remain untested.
Future Directions: Advance ZH-1a to GLP toxicology and IND-enabling studies; develop companion biomarkers (HMGB1 levels, redox state) and optimize dosing windows for late-phase sepsis in early-phase trials.
Damage-associated molecular patterns (DAMPs) are key mediators of inflammatory disease, among which HMGB1 is a prototypical extracellular alarmin and an attractive therapeutic target. Here, we report ZH-1a, a high-affinity DNA aptamer (Kd = 2.1 nM) identified through SELEX and sequence optimization, that preferentially recognizes the proinflammatory B-box region of HMGB1. ZH-1a functions as an extracellular HMGB1-neutralizing aptamer and suppresses HMGB1-induced inflammatory signaling, including cytokine secretion and NF-κB activation in macrophages. In vivo, ZH-1a reduced late-phase systemic inflammation and multiorgan injury in LPS-induced endotoxemia, improved survival in polymicrobial sepsis, and attenuated inflammatory responses and organ damage in an HMGB1-challenge model. In addition, ZH-1a alleviated joint inflammation and structural damage in collagen-induced arthritis, and further enhanced the therapeutic efficacy of methotrexate. Together, these findings establish ZH-1a as a promising anti-inflammatory aptamer targeting HMGB1 and support aptamer-based neutralization of pathogenic extracellular HMGB1 as a therapeutic strategy for inflammatory disease.
2. High-throughput antigen discovery using Functional Genomic Vaccinology (FGV) identifies protective Streptococcus pneumoniae vaccine candidates.
FGV integrates genome-wide prediction, proteome-scale arrays, and immunogenicity testing to identify pneumococcal antigens. A four-antigen multicomponent vaccine protected mice from pneumonia and sepsis, highlighting a scalable path to vaccines addressing invasive pneumococcal disease.
Impact: Delivers a generalizable, experimentally grounded pipeline for rapid bacterial antigen discovery and demonstrates protection against sepsis in vivo, accelerating vaccine development against major sepsis pathogens.
Clinical Implications: Supports development of multicomponent pneumococcal vaccines that could reduce invasive disease and sepsis burden. Human immunogenicity and functional assays can guide translation toward clinical candidates.
Key Findings
- FGV expressed 222 conserved S. pneumoniae proteins and identified IgG responses in 40% via protein microarray.
- Human sera reactivity prioritized 22 antigens for deeper evaluation, including Th17 responses.
- A four-antigen multicomponent vaccine protected mice from pneumonia and sepsis; epitope mapping revealed protective sites.
Methodological Strengths
- End-to-end high-throughput platform integrating prediction, screening, and in vivo functional validation.
- Use of human sera to prioritize antigens enhances translational relevance.
Limitations
- Protection demonstrated in mice; human clinical efficacy remains to be established.
- Antigen breadth and serotype coverage in diverse populations require further study.
Future Directions: Advance prioritized antigens to GMP-grade formulations, assess functional opsonophagocytic and mucosal immunity in humans, and evaluate multicomponent vaccine efficacy in phase 1/2 trials.
The discovery of protective antigens remains a major bottleneck in bacterial vaccine development. To overcome this limitation, we present Functional Genomic Vaccinology (FGV), a high-throughput antigen discovery platform integrating genome-wide antigen prediction, proteome-scale screening, and experimental immunogenicity validation to identify protective bacterial antigens. Using FGV, 222 conserved S. pneumoniae proteins are expressed in vitro, incorporated into a protein microarray, and coupled to magnetic beads for mouse vaccination. Protein array analysis shows significant IgG responses in 40% of the screened proteins. Antigen-specific responses measured in human sera guide the prioritisation of 22 candidates, which undergo further studied for their serological and Th17 responses. Four antigens combined in a multicomponent vaccine induces protection from pneumonia and sepsis in mice, with epitope mapping revealing potential protective sites for each protein. These results establish FGV as a scalable, experimentally driven approach for bacterial vaccine discovery and demonstrate its applicability in developing protective pneumococcal vaccines.
3. Down-Regulation of TFEB With Defective Autophagy in the Susceptibility of Aging Kidneys to Septic Acute Kidney Injury.
Aging kidneys show impaired autophagy activation and TFEB down-regulation, increasing susceptibility to SA-AKI. Restoring autophagy via TFEB overexpression or pharmacologic activation (C1) and using TAT-Beclin-1 protects senescent tubular cells and reduces LPS-induced AKI in vivo.
Impact: Identifies TFEB-regulated autophagy failure as a mechanistic driver of SA-AKI in aging, and demonstrates rescue with TFEB activation, highlighting a tractable therapeutic pathway for a high-risk group.
Clinical Implications: Supports exploring TFEB activation and autophagy-enhancing strategies to prevent or attenuate SA-AKI in older adults, with potential for biomarker-guided risk stratification.
Key Findings
- Aging kidneys exhibit impaired autophagy activation in response to septic AKI.
- Single-cell sequencing implicates TFEB among age-altered autophagy genes.
- TFEB overexpression and pharmacologic activation (C1) restore autophagy and protect against LPS-induced tubular injury; TAT-Beclin-1 reduces apoptosis/inflammation in senescent tubular cells.
Methodological Strengths
- Convergent in vivo, in vitro, and single-cell transcriptomic approaches.
- Pharmacologic and genetic rescue experiments strengthen causality.
Limitations
- Mouse models and LPS injury may not fully capture human SA-AKI heterogeneity.
- Translational relevance of C1 dosing and safety in humans is unknown.
Future Directions: Validate TFEB/autophagy biomarkers in human SA-AKI cohorts and evaluate TFEB activators with renal-targeted delivery in aged large-animal sepsis models.
Sepsis-associated acute kidney injury (SA-AKI) is a common and devastating disease that has a significantly higher incidence and greater severity in elderly patients, but the molecular basis underlying SA-AKI in the elderly is largely unknown. Recent studies have proved autophagy as an intrinsic protective mechanism against AKI; however, the role and regulation of autophagy in aging kidneys remain unclear. Here we demonstrate that defective autophagy activation in aging kidneys is a key to their susceptibility to SA-AKI. In our experiments, the ability of autophagy activation was impaired in aging kidneys in response to SA-AKI in mice. In vitro, activation of autophagy with TAT-Beclin-1 peptide mitigated lipopolysaccharide (LPS)-induced apoptosis and inflammation in senescent renal proximal tubular cells. Single-cell sequencing revealed significant age-related alterations in autophagy-associated genes in septic AKI, including TFEB. Overexpression of TFEB could partially restore autophagic activity in senescent renal tubular cells and protect them from LPS-induced damage. Moreover, in vivo treatment with the curcumin analog C1 (a TFEB activator) enhanced autophagic function in aging kidneys and reduced LPS-induced AKI. These results demonstrate the defective autophagy activation in aging kidneys, which contributes to the SA-AKI sensitivity and susceptibility in the elderly, suggesting a therapeutic strategy by enhancing autophagy.